Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer

被引：0
|
作者：
Nieva, J. J.
Webb, W.
Siuzdak, G.
机构：
[1] Scripps Canc Ctr, La Jolla, CA USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19622
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
    Allegrini, G.
    Falcone, A.
    Fioravanti, A.
    Barletta, M. T.
    Orlandi, P.
    Loupakis, F.
    Cerri, E.
    Masi, G.
    Di Paolo, A.
    Kerbel, R. S.
    Danesi, R.
    Del Tacca, M.
    Bocci, G.
    BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1312 - 1319
  • [2] A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
    G Allegrini
    A Falcone
    A Fioravanti
    M T Barletta
    P Orlandi
    F Loupakis
    E Cerri
    G Masi
    A Di Paolo
    R S Kerbel
    R Danesi
    M Del Tacca
    G Bocci
    British Journal of Cancer, 2008, 98 : 1312 - 1319
  • [3] Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
    Rouits, E.
    Charasson, V.
    Petain, A.
    Boisdron-Celle, M.
    Delord, J-P
    Fonck, M.
    Laurand, A.
    Poirier, A-L
    Morel, A.
    Chatelut, E.
    Robert, J.
    Gamelin, E.
    BRITISH JOURNAL OF CANCER, 2008, 99 (08) : 1239 - 1245
  • [4] Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer
    Oyaga-Iriarte, Esther
    Insausti, Asier
    Sayar, Onintza
    Aldaz, Azucena
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (04) : 529 - 542
  • [5] Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
    E Rouits
    V Charasson
    A Pétain
    M Boisdron-Celle
    J-P Delord
    M Fonck
    A Laurand
    A-L Poirier
    A Morel
    E Chatelut
    J Robert
    E Gamelin
    British Journal of Cancer, 2008, 99 : 1239 - 1245
  • [6] Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer
    Esther Oyaga-Iriarte
    Asier Insausti
    Onintza Sayar
    Azucena Aldaz
    European Journal of Clinical Pharmacology, 2019, 75 : 529 - 542
  • [7] Irinotecan in colorectal cancer in elderly patients with advanced colorectal cancer
    Sastre, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S22 - S22
  • [8] Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan
    Gonzalez-Baron, M.
    Blanco, M.
    Feliu, J.
    Gomez, C.
    Casado, E.
    Castro, J.
    Belda-Iniesta, C.
    Garrido, M.
    Aguayo, C.
    Campos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
    Zhu, Jinwei
    Zhang, Yicui
    Zhao, Yixin
    Zhang, Jingwei
    Hao, Kun
    He, Hua
    PHARMACEUTICS, 2023, 15 (09)
  • [10] Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient
    Hamada, A
    Aoki, A
    Terazaki, H
    Ito, K
    Yokoo, K
    Sasaki, Y
    Saito, H
    THERAPEUTIC DRUG MONITORING, 2005, 27 (04) : 536 - 538
12345